|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.98 USD | +0.35% |
|
-.--% | - |
| 05-18 | Endologix LLC acquired Pounce? Thrombectomy System from Surmodics, Inc. | CI |
| 12-09 | Surmodics, Inc. acquired certain assets from Biocoat, Incorporated. | CI |
Company Valuation: SurModics
Data adjusted to current consolidation scope
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 617.1 | 531.1 | 771.3 | 425.8 | 453.6 | 553.3 |
| Change | - | -13.93% | 45.22% | -44.8% | 6.53% | 21.98% |
| Enterprise Value (EV) 1 | 561.8 | 473.8 | 746.1 | 421.6 | 441.5 | 546.4 |
| Change | - | -15.66% | 57.47% | -43.5% | 4.72% | 23.77% |
| P/E | 83.2x | 486x | 185x | -15.5x | -292x | -47.3x |
| PBR | 5.04x | 4.06x | 5.52x | 3.93x | 3.79x | 4.67x |
| PEG | - | -5.7x | 1x | 0x | 3.1x | -0x |
| Capitalization / Revenue | 6.17x | 5.6x | 7.34x | 4.26x | 3.42x | 4.39x |
| EV / Revenue | 5.61x | 4.99x | 7.1x | 4.22x | 3.33x | 4.33x |
| EV / EBITDA | 39.6x | 78.8x | 61.3x | -32.6x | 31.3x | 81x |
| EV / EBIT | 81.9x | -379x | 180x | -19.1x | 78.8x | -281x |
| EV / FCF | -39.1x | 67.3x | 150x | -62.6x | 31.3x | 79.6x |
| FCF Yield | -2.56% | 1.49% | 0.67% | -1.6% | 3.2% | 1.26% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.55 | 0.08 | 0.3 | -1.96 | -0.11 | -0.82 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 100.1 | 94.86 | 105.1 | 99.95 | 132.6 | 126.1 |
| EBITDA 1 | 14.17 | 6.012 | 12.17 | -12.94 | 14.12 | 6.749 |
| EBIT 1 | 6.857 | -1.251 | 4.155 | -22.08 | 5.603 | -1.945 |
| Net income 1 | 7.592 | 1.123 | 4.237 | -27.27 | -1.536 | -11.54 |
| Net Debt 1 | -55.29 | -57.32 | -25.16 | -4.192 | -12.1 | -6.87 |
| Reference price 2 | 45.74 | 38.91 | 55.60 | 30.40 | 32.09 | 38.78 |
| Nbr of stocks (in thousands) | 13,491 | 13,650 | 13,872 | 14,005 | 14,134 | 14,267 |
| Announcement Date | 12/3/19 | 12/2/20 | 11/24/21 | 11/23/22 | 11/22/23 | 11/20/24 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 615M | |
| 22.8x | 3.43x | 12.87x | 2.76% | 161B | |
| 17.95x | 3.16x | 11.13x | 3.74% | 101B | |
| 15.86x | 0.18x | 11.37x | 0.82% | 56.12B | |
| 32.74x | 7.95x | 20.8x | 1.23% | 53.35B | |
| 38.1x | 3.02x | 10.38x | 2.52% | 42.13B | |
| 39.95x | 1.44x | 12.67x | 0.2% | 35.29B | |
| 28.13x | 5.01x | 15.96x | -.--% | 26.57B | |
| 43.35x | 7.52x | 27.13x | 0.25% | 25.79B | |
| 23.36x | 3.42x | 12.28x | 1.24% | 20.69B | |
| Average | 29.14x | 3.90x | 14.96x | 1.42% | 52.25B | |
| Weighted average by Cap. | 25.83x | 3.60x | 13.80x | 2.07% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SRDX Stock
- Valuation SurModics
Select your edition
All financial news and data tailored to specific country editions
